CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits

por Vieira, Fernando G., Hatzipetros, Theo, Thompson, Kenneth, Moreno, Andy J., Kidd, Joshua D., Tassinari, Valerie R., Levine, Beth, Perrin, Steven, Gill, Alan
Publicado 2017

SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS

por Gill, Cindy, Phelan, James P., Hatzipetros, Theo, Kidd, Joshua D., Tassinari, Valerie R., Levine, Beth, Wang, Monica Z., Moreno, Andrew, Thompson, Kenneth, Maier, Marcel, Grimm, Jan, Gill, Alan, Vieira, Fernando G.
Publicado 2019

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

por Berry, James D., Paganoni, Sabrina, Atassi, Nazem, Macklin, Eric A., Goyal, Namita, Rivner, Michael, Simpson, Ericka, Appel, Stanley, Grasso, Daniela L., Mejia, Nicte I., Mateen, Farrah, Gill, Alan, Vieira, Fernando, Tassinari, Valerie, Perrin, Steven
Publicado 2017

Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS

por Vieira, Fernando G., Ping, Qinggong, Moreno, Andy J., Kidd, Joshua D., Thompson, Kenneth, Jiang, Bingbing, Lincecum, John M., Wang, Monica Z., De Zutter, Gerard S., Tassinari, Valerie R., Levine, Beth, Hatzipetros, Theo, Gill, Alan, Perrin, Steven
Publicado 2015